Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation

Clinical Infectious Diseases

Volumn 48, Issue 10, 2009, Pages 1392-1401

  Cordonnier, Catherine ^a   Labopin, Myriam ^b   Chesnel, Virginie ^b   Ribaud, Patricia ^c   De La Camara, Rafael ^e   Martino, Rodrigo ^f   Ullmann, Andrew J ^g   Parkkali, Terttu ^j   Locasciulli, Anna ^k   Yakouben, Karima ^d   Pauksens, Karlis ^l   Einsele, Hermann ^h   Niederwieser, Dietger ⁱ   Apperley, Jane ⁿ   Ljungman, Per ^m  

^a HENRI MONDOR HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f Hospital Sant Pau   (Spain)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

ⁱ UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k San Camillo Teaching Hospital   (Italy)

^l UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ HAMMERSMITH HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; BACTERIUM ANTIBODY; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; EARLY INTERVENTION; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNIZATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROTYPE; SIDE EFFECT; SKIN; TREATMENT RESPONSE; BLOOD; EUROPE; IMMUNOLOGY; MIDDLE AGED; STEM CELL TRANSPLANTATION; TIME;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHILD; EUROPE; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; STEM CELL TRANSPLANTATION; TIME FACTORS; YOUNG ADULT;

EID: 65549089986     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598324     Document Type: Article

References (30)

1. Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus host disease is associated with long term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000;95:3683-6.
2. Engelhard D, Cordonnier C, Shaw PJ, et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol 2002;117:444-50.
3. Winston DJ, Schiffman G, Wang DC, et al. Pneumococcal infections after human bone marrow transplantation. Ann Intern Med 1979;91:835-41.
4. Giebink G, Warkentin P, Ralsay N, et al. Titers of antibody to pneu- mococci in allogeneic bone marrow transplant recipients. J Infect Dis 1986;154:590-6.
5. Hammarstrom V, Pauksen K, Azinge J, Oberg G, Ljungman P. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction. Support Care Cancer 1993;1:195-9.
6. Lortan JE, Vellodi A, Jurges ES, Hugh-Jones K. Class- and subclass-specific pneumococcal antibody levels and response to immunization after bone marrow transplantation. Clin Exp Immunol 1992;88:512-9.
7. Winston DJ, Ho WG, Schiffman G, Champlin RE, Feig SA, Gale RP. Pneumococcal vaccination ofrecipients ofbone marrowtransplants. Arch Intern Med 1983;143:1735-7.
8. Avanzini MA, Carra AM, Maccario R, et al. Antibody response to pneu- mococcal vaccine in children receiving bone marrow transplantation. J Clin Immunol 1995;15:137-44.
9. Molrine DC, Guinan EC, Antin JH, et al. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood 1996;87:3012-18.
10. Ljungman P, Engelhard D, Da La Camara R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005;35:737-46.
11. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic among hematopoietic stem cell transplant recipients: recommendations of the CDC, the Infectious Diseases Society of America, and the American SocietyofBlood and MarrowTransplantation. MMWR Morb Mortal Wkly Rep 2000;49(RR-10):1-125.
12. Barra A, Cordonnier C, Precziosi MP, et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis 1992;166:1021-8.
13. Guinan EC, Molrine DC, Antin JH, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 1994;57:677-84.
14. Parkkali T, Kayhty H, Ruutu T, Volin L, Eskola J, Ruutu P. A comparison of early and late vaccination with Haemophilus influenzae type b and pneumococcal polysaccharide vaccines after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;18:961-7.
15. Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of hep- tavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999;18:757-63.
16. Molrine D, Antin JH, Guinan EC, et al. Donor immunization with pneu- mococal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic stem cell transplantation. Blood 2003;101:831-6.
17. Meisel R, Kuypers L, Dirksen U, et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic stem cell transplantation. Blood 2007;109:2322-6.
18. Storek J, Mendelman PM, Witherspoon RP, et al. IgG response to pneu- mococcal polysaccharide-protein conjugate appears similar to IgG response to polysaccharide in bone marrow transpant recipients and healthy adults. Clin Infect Dis 1997;25:1253-5.
19. Armitage JO. Bone marrow transplantation. N Engl J Med 1994;330:827-38.
20. Conception NF, Frash CE. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001;8:266-72.
21. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immuno- genicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-95.
22. Pocock SJ. The pros and cons of non-inferiority trials. Fundam Clin Pharmacol 2003;17:483-90.
23. Kumar D, Chen MH, Welsh B, et al. A randomized, double blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis 2007;45:1576-82.
24. World Health Organization Expert Committee on Biological Standardization. Pneumococcal conjugate vaccine: recommendations for production and quality control of pneumococcal conjugate vaccines. 2003. Available at: http://www.who.int/biologicals/pneumococcal-conjugate-Vaccines-Recomm-Nov-2003. Accessed September 2008.
25. De Roux A, Schmoele-Thoma B, SIber GR, et al. Comparison of pneu- mococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008;46:1015-23.
26. Debbache K, Varon E, Hicheri Y, et al. Epidemiology of S. pneumoniae infection in hematology patients in Ile de France: serotypes covered by the polysaccharide 23-valent (PS23) and the heptavalent conjugate vaccine [abstract]. Blood 2007;110:4963.
27. Hausdorff WP, Hajieh R, Al-Mazrou A, Shibl A, Soriano-Gabarro M. The epidemiology of pneumococcal, meningoccal, and Haemophilus disease in the Middle East and North Africa (MENA) region-current status and needs. Vaccine 2007;25:1935-4.
28. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumo- niae.NEnglJMed 2006;354:1455-63.
29. Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal vaccine. Clin Infect Dis 2007;44:1569-76.
30. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007;26:123-8.